Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hepatitis HELP
Based on 54,412 articles published since 2007
|||| 11 

These are the 54412 published articles about Hepatitis that originated from Worldwide during 2007-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Hepatitis B vaccines: WHO position paper – July 2017. 2017

Anonymous7480912. · ·Wkly Epidemiol Rec · Pubmed #28685564.

ABSTRACT: -- No abstract --

2 Guideline Position paper on treatment of hepatitis C in Romania, 2017. Part one. 2017

Gheorghe, Liana / Sporea, Ioan / Iacob, Speranţa / Şirli, Roxana / Trifan, Anca / Dobru, Daniela / Diculescu, Mircea / Stanciu, Carol / Pascu, Oliviu / Acalovschi, Monica / Brisc, Ciprian / Cijevschi, Cristina / Gheorghe, Cristian / Spârchez, Zeno / Rogoveanu, Ion / Dumitrascu, Dan. ·Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. · Dept. of Gastroenterology and Hepatology, Victor Babeș University of Medicine and Pharmacy, Timișoara, Romania. · Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. msiacob@gmail.com. · Institute of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania. · Gastroenterology Department, University of Medicine and Pharmacy, Târgu Mureș, Romania. · Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · Gastroenterology Department, Faculty of Medicine and Pharmacy, Oradea, Romania. · Gastroenterology Department, University of Medicine and Pharmacy, Craiova, Romania. · 2nd Medical Clinic, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ·J Gastrointestin Liver Dis · Pubmed #28617888.

ABSTRACT: BACKGROUND AND AIMS: Hepatitis C Virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania the mean prevalence is about 3%. New treatments became available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country. METHODOLOGY: A group of recognized experts was created who screened the available literature and the major available guidelines. A list of items requiring attention has been created. These items were discussed and rated. Decisions were taken by consensus. RECOMMENDATIONS: We present here the first of the two parts of our Society's recommendations for chronic HCV infection treatment. An agreement was reached regarding the diagnostic tools, the assessment of severity and the up-dated therapy schedules. CONCLUSIONS: This Position Paper represents a guide for the assessment and the therapy of HCV infection. The recommendations are in concordance with other guidelines but are applied to the real-life conditions in this country.

3 Guideline Recommendations on hepatitis C screening for adults. 2017

Grad, Roland / Thombs, Brett / Tonelli, Marcello / Bacchus, Maria / Birtwhistle, Richard / Klarenbach, Scott / Singh, Harminder / Dorais, Veronique / Holmes, Nathalie / Martin, Wendy / Rodin, Rachel / Jaramillo Garcia, Alejandra / Anonymous1961047. ·Department of Family Medicine, McGill University, Montréal, Que. · Department of Psychiatry, McGill University, Montréal, Que. · Department of Medicine, University of Calgary, Calgary, Alta. · Departments of Family Medicine and Public Health Sciences, Queen’s University, Kingston, Ont. · Department of Medicine, University of Alberta, Edmonton, Alta. · Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Man. · Public Health Agency of Canada, Ottawa, Ont. ·CMAJ · Pubmed #28438952.

ABSTRACT: -- No abstract --

4 Guideline International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. 2017

Terrault, Norah A / Berenguer, Marina / Strasser, Simone I / Gadano, Adrian / Lilly, Les / Samuel, Didier / Kwo, Paul Y / Agarwal, Kosh / Curry, Michael P / Fagiuoli, Stefano / Fung, James Y Y / Gane, Edward / Brown, Kimberly A / Burra, Patrizia / Charlton, Michael / Pessoa, Mario G / McCaughan, Geoff W. ·1 Hepatology and Transplant Surgery, University of California San Francisco, San Francisco, CA. 2 Liver Unit, Hospital Universitario y Politécnico La Fe, Universidad Valencia and CIBEREHD, Valencia, Spain. 3 Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. 4 Liver Unit, Hospital Italiano, Buenos Aires, Argentina. 5 Multiorgan Transplant, University Health Network/Toronto General Hospital, Toronto Hospital, Toronto, Ontario, Canada. 6 Hepatology, AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, Université Paris-Saclay, Villejuif, France. 7 Department of Medicine, Stanford University, Palo Alto, CA. 8 Institute of Liver Studies, Kings College Hospital, London, United Kingdom. 9 Liver Center, Beth Israel Deaconess Medical Center, Boston, MA. 10 Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Begamo, Italy. 11 The Liver Transplant Center, Queen Mary Hospital, Hong Kong. 12 New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. 13 Division of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI. 14 Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy. 15 Utah Intermountain Transplant and Regenerative Medicine Center, Salt Lake City, UT. 16 Division of Gastroenterology and Hepatology, University of São Paulo School of Medicine, São Paulo, Brazil. 17 Australian National Liver Transplant Unit, Centenary Research Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. ·Transplantation · Pubmed #28437388.

ABSTRACT: -- No abstract --

5 Guideline International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. 2017

Terrault, Norah A / McCaughan, Geoff W / Curry, Michael P / Gane, Edward / Fagiuoli, Stefano / Fung, James Y Y / Agarwal, Kosh / Lilly, Les / Strasser, Simone I / Brown, Kimberly A / Gadano, Adrian / Kwo, Paul Y / Burra, Patrizia / Samuel, Didier / Charlton, Michael / Pessoa, Mario G / Berenguer, Marina. ·1 Hepatology and Transplant Surgery, University of California San Francisco, San Francisco, CA. 2 Australian National Liver Transplant Unit, Centenary Research Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. 3 Liver Center, Beth Israel Deaconess Medical Center, Boston, MA. 4 New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. 5 Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Begamo, Italy. 6 The Liver Transplant Center, Queen Mary Hospital, High West, Hong Kong. 7 Institute of Liver Studies, Kings College Hospital, London, United Kingdom. 8 Multiorgan Transplant, University Health Network/Toronto General Hospital, Toronto, Ontario, Canada. 9 Australian National Liver Transplant Unit, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia. 10 Division of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI. 11 Liver Unit, Hospital Italiano, Buenos Aires, Argentina. 12 Department of Medicine, Stanford University, Palo Alto, CA. 13 Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy. 14 Hepatology, AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, Université Paris-Saclay, Villejuif, France. 15 Utah Intermountain Transplant and Regenerative Medicine Center, Salt Lake City, UT. 16 Division of Gastroenterology and Hepatology, University of São Paulo School of Medicine, São Paulo, Brazil. 17 Liver Unit, Hospital Universitario y Politécnico La Fe, Universidad Valencia and CIBEREHD, Valencia, Spain. ·Transplantation · Pubmed #28437387.

ABSTRACT: -- No abstract --

6 Guideline Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 1–2 February 2017 meeting. 2017

Anonymous770904. · ·Wkly Epidemiol Rec · Pubmed #28413874.

ABSTRACT: -- No abstract --

7 Guideline American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. 2017

Jacobson, Ira M / Lim, Joseph K / Fried, Michael W. ·Department of Medicine, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ijacobson@chpnet.org. · Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut. · Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina. ·Gastroenterology · Pubmed #28344022.

ABSTRACT: Chronic hepatitis C virus infection is well-recognized as a common blood-borne infection with global public health impact affecting 3 to 5 million persons in the United States and more than 170 million persons worldwide. Chronic hepatitis C virus infection is associated with significant morbidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma. Current therapies with all-oral direct-acting antiviral agents are associated with high rates of sustained virologic response (SVR), generally exceeding 90%. SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver transplantation, and both liver-related and all-cause mortality. However, a subset of patients who achieve SVR will remain at long-term risk for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related mortality. Limited evidence is available to guide clinicians on which post-SVR patients should be monitored vs discharged, how to monitor and with which tests, how frequently should monitoring occur, and for how long. In this clinical practice update, available evidence and expert opinion are used to generate best practice recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

8 Guideline No. 342-Hepatitis B and Pregnancy. 2017

Castillo, Eliana / Murphy, Kellie / van Schalkwyk, Julie. ·Calgary, AB. · Toronto, ON. · Vancouver, BC. ·J Obstet Gynaecol Can · Pubmed #28284515.

ABSTRACT: OBJECTIVE: To review the epidemiology, natural history, evaluation, and treatment of hepatitis B virus (HBV) infection during pregnancy. This will aid obstetric care providers in counseling their patients regarding perinatal risks and management options available to pregnant women with hepatitis B. OUTCOMES: Outcomes evaluated include thresholds for HBV anti-viral treatment for prevention of perinatal transmission and for invasive procedures during pregnancy for women with hepatitis B infection. EVIDENCE: Medline, EMBASE, and CINAHL were searched for articles in English on subjects related to HBV infection, pregnancy, and perinatal transmission from 1966 to March 2016. Results were restricted to systematic reviews, randomized controlled trials/controlled clinical trials, and observational studies. Other (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical speciality societies. VALIDATION METHODS: The quality of the evidence is rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table 1). Recommendations for practice are ranked according to the method described in this Report. GUIDELINE UPDATE: The guideline will be reviewed 5 years after publication to decide if an update is required. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations. SPONSORS: This guideline was developed with resources funded by the Society of Obstetricians and Gynaecologists of Canada.

9 Guideline Practice Alert: ACIP vaccine update, 2017. 2017

Campos-Outcalt, Doug. ·Medical Director, Mercy Care Plan, Phoenix, AZ, USA. Email:campos-outcaltd@mercycareplan.com. ·J Fam Pract · Pubmed #28249054.

ABSTRACT: HIV infection is now an indication for meningococcus vaccination and HPV vaccine dosing is simpler for patients ⟨15 years.

10 Guideline ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. 2017

Farraye, Francis A / Melmed, Gil Y / Lichtenstein, Gary R / Kane, Sunanda V. ·Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA. · Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. · Division of Gastroenterology, Hospital of the University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. ·Am J Gastroenterol · Pubmed #28071656.

ABSTRACT: Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy. In particular, documentation of up to date vaccinations are crucial as IBD patients are often treated with long-term immune-suppressive therapies and may be at increased risk for infections, many of which are preventable with vaccinations. Health maintenance issues addressed in this guideline include identification, safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer as well as identification of depression and anxiety and smoking cessation. To accomplish these health maintenance goals, coordination between the primary care provider, gastroenterology team and other specialists is necessary.

11 Guideline  Joint Society statement for elimination of viral hepatitis. 2017

Brahm, Javier / Castera, Laurent / Hou, Jinlin / Lindor, Keith. ·Latin American Association for the Study of the Liver. · European Association of the Study of the Liver. · Asian Pacific Association for the Study of the Liver. · American Association for the Study of Liver Disease. ·Ann Hepatol · Pubmed #28051786.

ABSTRACT: -- No abstract --

12 Guideline ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. 2017

Kwo, Paul Y / Cohen, Stanley M / Lim, Joseph K. ·Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA. · Digestive Health Institute, University Hospitals Cleveland Medical Center and Division of Gastroenterology and Liver Disease, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. · Yale Viral Hepatitis Program, Yale University School of Medicine, New Haven, Connecticut, USA. ·Am J Gastroenterol · Pubmed #27995906.

ABSTRACT: Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation determined to be of hepatic origin, testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken. Total bilirubin elevation can occur in either cholestatic or hepatocellular diseases. Elevated total serum bilirubin levels should be fractionated to direct and indirect bilirubin fractions and an elevated serum conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings. A liver biopsy may be considered when serologic testing and imaging fails to elucidate a diagnosis, to stage a condition, or when multiple diagnoses are possible.

13 Guideline Post-exposure prophylaxis guidelines for children and adolescents potentially exposed to HIV. 2017

Bamford, Alasdair / Tudor-Williams, Gareth / Foster, Caroline. ·Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, London, UK. · Department of Paediatric Infectious Diseases, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK. ·Arch Dis Child · Pubmed #27974330.

ABSTRACT: UK guidelines for HIV post-exposure prophylaxis (PEP) in adults have recently been updated. Indications for PEP have been modified and there has been a change in the recommended antiretroviral therapy for adults to a combination of raltegravir with tenofovir and emtricitabine (Truvada). Raltegravir and tenofovir are now available in paediatric formulations and offer improved safety and tolerability over previously recommended ritonavir-boosted lopinavir with zidovudine. This guideline provides recommendations for those caring for children potentially exposed to HIV and other bloodborne viruses in primary care, emergency departments, secondary care and specialist paediatric HIV centres.

14 Guideline [Management following sexual exposure to HIV, HVB and HVC]. 2016

Timsit, F-J / Vernay-Vaisse, C / Derancourt, C / Viraben, R / Chartier, C / Spenatto, N / Anonymous12440885. ·Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. Electronic address: centre.mst@aphp.fr. · CIDAG/CIDDIST MDS Aubagne, 10, allée Antide-Boyer, 13400 Aubagne, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort de France, France. · Service de dermatologie et médecine sociale, pôle santé publique et médecine sociale, hôpital La Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · 24, place Kléber, 67000 Strasbourg, France. ·Ann Dermatol Venereol · Pubmed #27776810.

ABSTRACT: -- No abstract --

15 Guideline [STD and STI screening]. 2016

Vernay-Vaïsse, C / Spenatto, N / Derancourt, C / Timsit, F-J / Fouéré, S / Pinault, A-L / Anonymous11440885. ·CIDAG/CIDDIST CD 13, DPMISP, 4, quai d'Arenc, CS 70095, 13304 Marseille cedex 02, France. Electronic address: chantal.vernayvaisse@cg13.fr. · Pôle santé publique et médecine sociale, service de dermatologie et médecine sociale, hôpital La-Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort-de-France, Martinique. · Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. · 41, boulevard Henri IV, 75004 Paris, France. · Service de dermatologie, hôpital de Brabois, CHU de Nancy, 5, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. ·Ann Dermatol Venereol · Pubmed #27773502.

ABSTRACT: -- No abstract --

16 Guideline Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. 2016

Easterbrook, Philippa J / Anonymous3871012. ·Global Hepatitis Programme, HIV Department, World Health Organization, Geneva, Switzerland. Electronic address: easterbrookp@who.int. · Global Hepatitis Programme, HIV Department, World Health Organization, Geneva, Switzerland. ·J Hepatol · Pubmed #27641988.

ABSTRACT: Testing and diagnosis of hepatitis C virus (HCV) infection is the gateway for access to both treatment and prevention services, and crucial for an effective hepatitis epidemic response. In contrast to HIV, a systematic approach to hepatitis C testing has been fragmented and limited to a few countries, and there remains a large burden of undiagnosed cases globally. Key challenges in the current hepatitis testing response, include lack of simple, reliable, and low cost diagnostic tests, laboratory capacity, and testing facilities; inadequate data to guide country-specific hepatitis testing approaches and who to test; stigmatization and social marginalization of some groups with or at risk of viral hepatitis; and lack of international or national guidelines on hepatitis testing for resource-limited settings. New tools to support the hepatitis global response include the 2016 Global Hepatitis Health Sector Strategy which include targets for testing and diagnosis, and World Health Organization (WHO) 2016 hepatitis testing guidelines for adults, adolescents, and children in low- and middle-income countries. The testing guidance complements recent published WHO guidance on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These testing guidelines outline the public health approach to strengthening and expanding current testing practices for HCV and HBV and address what serological and virological assays to use, and who to test, as well as interventions to promote linkage to prevention and care after testing. They are intended for use across all age groups and populations. See boxes for key recommendations. Future directions and innovations in viral hepatitis testing include use of point-of-care assays for nucleic acid testing (NAT) and core antigen; validation of dried blood spots specimens with different commercial serological and NAT assays; multiplex and polyvalent platforms for integrated testing of HIV, HBV and HCV; and potential for self-testing.

17 Guideline SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016

Alghamdi, Abdullah S / Alghamdi, Mohammed / Sanai, Faisal M / Alghamdi, Hamdan / Aba-Alkhail, Faisal / Alswat, Khalid / Babatin, Mohammed / Alqutub, Adel / Altraif, Ibrahim / Alfaleh, Faleh. ·Department of Medicine, Gastroenterology Unit, King Fahad Hospital, Jeddah, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Fahd Military Complex, Dhahran, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia. · Department of Hepatobiliary Sciences and Liver Transplantation King Abdulaziz Medical City, and King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. · Department of Medicine, Gastroenterology unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia. · Department of Medical Specialties, Gastroenterology and Hepatology Section, King Fahad Medical City, Riyadh, Saudi Arabia. ·Saudi J Gastroenterol · Pubmed #27538727.

ABSTRACT: -- No abstract --

18 Guideline British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. 2016

Warren, R B / Weatherhead, S C / Smith, C H / Exton, L S / Mohd Mustapa, M F / Kirby, B / Yesudian, P D. ·The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD, U.K. · Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, U.K. · St John's Institute of Dermatology, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, U.K. · British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, U.K. · St Vincent's University Hospital, Elm Park, Dublin, Ireland. · Glan Clwyd Hospital, Sarn Lane, Rhyl, LL18 5UJ, U.K. ·Br J Dermatol · Pubmed #27484275.

ABSTRACT: -- No abstract --

19 Guideline APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016

Omata, Masao / Kanda, Tatsuo / Wei, Lai / Yu, Ming-Lung / Chuang, Wang-Long / Ibrahim, Alaaeldin / Lesmana, Cosmas Rinaldi Adithya / Sollano, Jose / Kumar, Manoj / Jindal, Ankur / Sharma, Barjesh Chander / Hamid, Saeed S / Dokmeci, A Kadir / Al-Mahtab, Mamun / McCaughan, Geofferey W / Wasim, Jafri / Crawford, Darrell H G / Kao, Jia-Horng / Yokosuka, Osamu / Lau, George K K / Sarin, Shiv Kumar. ·Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. momata-tky@umin.ac.jp. · The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. momata-tky@umin.ac.jp. · Graduate School of Medicine, Chiba University, Chiba, Japan. · Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China. · Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. · Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. · GI/Liver Division, Department of Internal Medicine, University of Benha, Banha, Egypt. · Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. · University Santo Tomas Hospital, Manila, Philippines. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh. · Royal Prince Alfred Hospital, Centenary Institute, University of Sydney, Sydney, Australia. · University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia. · National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. · The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China. ·Hepatol Int · Pubmed #27229718.

ABSTRACT: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

20 Guideline APASL consensus statements and recommendation on treatment of hepatitis C. 2016

Omata, Masao / Kanda, Tatsuo / Wei, Lai / Yu, Ming-Lung / Chuang, Wang-Long / Ibrahim, Alaaeldin / Lesmana, Cosmas Rinaldi Adithya / Sollano, Jose / Kumar, Manoj / Jindal, Ankur / Sharma, Barjesh Chander / Hamid, Saeed S / Dokmeci, A Kadir / Mamun-Al-Mahtab, ? / McCaughan, Geofferey W / Wasim, Jafri / Crawford, Darrell H G / Kao, Jia-Horng / Yokosuka, Osamu / Lau, George K K / Sarin, Shiv Kumar. ·Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-Shi, Yamanashi, 400-8506, Japan. hepint_omata@yahoo.co.jp. · The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hepint_omata@yahoo.co.jp. · Graduate School of Medicine, Chiba University, Chiba, Japan. · Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China. · Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. · Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. · GI/Liver Division, Department of Internal Medicine, University of Benha, Benha, Egypt. · Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. · University Santo Tomas Hospital, Manila, Philippines. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh. · Centenary Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. · School of Medicine, University of Queensland, Woolloongabba, QLD, 4102, Australia. · National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. · The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China. ·Hepatol Int · Pubmed #27130427.

ABSTRACT: The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409-435, 2012)". The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.

21 Guideline Hepatitis E in Children: A Position Paper by the ESPGHAN Hepatology Committee. 2016

Fischler, Björn / Baumann, Ulrich / Dezsofi, Antal / Hadzic, Nedim / Hierro, Loreto / Jahnel, Jörg / McLin, Valérie / Nobili, Valerio / Smets, Francoise / Verkade, Henkjan / Debray, Dominique. ·*Department of Paediatrics, CLINTEC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden †Division of Paediatric Gastroenterology and Hepatology, Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany ‡First Department of Paediatrics, Semmelweis University, Budapest, Hungary §Paediatric Centre for Hepatology, Gastroenterology and Nutrition, King's College Hospital, London, UK ||Paediatric Hepatology Service, Hospital Infantil Universitario "La Paz," Madrid, Spain ¶Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Austria #Paediatric Gastroenterology Unit, Department of Pediatrics, University Hospitals Geneva, Switzerland **Hepatometabolic Unit, Bambino Gesu Children's Hospital, Rome, Italy ††Pediatric Gastroenterology and Hepatology Unit, IREC, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium ‡‡Department of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands §§Pediatric Hepatology Unit, Hôpital NECKER-APHP, Paris, France. ·J Pediatr Gastroenterol Nutr · Pubmed #27050048.

ABSTRACT: BACKGROUND: Hepatitis E virus (HEV) is endemic in large parts of the developing world. Waterborne transmission of genotypes 1 or 2 commonly causes acute hepatitis, which is usually self-limited in healthy individuals. In addition, acute HEV infections also occur outside endemic areas, mostly related to foodborne transmission of HEV genotype 3. A growing number of publications in the last decade have reported chronic infection progressing to cirrhosis in immunosuppressed patients. It has also been suggested that HEV transmission may occur via contaminated blood products. This publication aims to provide recommendations for diagnosis, prevention, and treatment of HEV infection, particularly in children after solid organ transplantation. METHODS: A systematic PubMed literature search on HEV infection from 1990 to January 2016 was performed focusing on pediatric studies. The existing body of evidence was reviewed and recommendations were agreed upon following discussion and unanimous agreement by all members of the ESPGHAN Hepatology Committee during a consensus meeting in January 2016. In the absence of randomized controlled studies these recommendations were considered to be expert opinions. KEY RECOMMENDATIONS: Immunocompetent children with increased transaminases and/or extrahepatic manifestations should be considered for testing for evidence of HEV infection. Immunocompromised children with increased aminotransferases should be repeatedly tested for HEV and may require therapeutic intervention.

22 Guideline KASL clinical practice guidelines: management of hepatitis C. 2016

Anonymous16410863. · ·Clin Mol Hepatol · Pubmed #27044763.

ABSTRACT: -- No abstract --

23 Guideline KASL clinical practice guidelines: management of chronic hepatitis B. 2016

Anonymous16400863. · ·Clin Mol Hepatol · Pubmed #27044762.

ABSTRACT: -- No abstract --

24 Guideline Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. 2016

Crabb, David W / Bataller, Ramon / Chalasani, Naga P / Kamath, Patrick S / Lucey, Michael / Mathurin, Philippe / McClain, Craig / McCullough, Arthur / Mitchell, Mack C / Morgan, Timothy R / Nagy, Laura / Radaeva, Svetlana / Sanyal, Arun / Shah, Vijay / Szabo, Gyongyi / Anonymous360860. ·Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, School of Medicine, Indianapolis, Indiana. Electronic address: dcrabb@iu.edu. · Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. · Division of Gastroenterology and Hepatology Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. · Gastroenterology Research Unit, Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. · Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin, Madison, Wisconsin. · Service Maladie de l'Appareil Digestif and INSERM U995 Univ Lille 2, CHRU Lille, France. · Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky. · Departments of Gastroenterology, Hepatology and Transplant Surgery, Cleveland Clinic, Cleveland, Ohio. · Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas. · VA Long Beach Healthcare System, Long Beach, California. · Department of Pathobiology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio. · Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. · Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, Virginia. · Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. ·Gastroenterology · Pubmed #26921783.

ABSTRACT: -- No abstract --

25 Guideline ACG Clinical Guideline: Liver Disease and Pregnancy. 2016

Tran, Tram T / Ahn, Joseph / Reau, Nancy S. ·Department of Medicine, Liver Transplant, Cedars Sinai Medical Center, Los Angeles, California, USA. · Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA. · Department of Medicine, Rush University, Chicago, Illinois, USA. ·Am J Gastroenterol · Pubmed #26832651.

ABSTRACT: Consultation for liver disease in pregnant women is a common and oftentimes vexing clinical consultation for the gastroenterologist. The challenge lies in the need to consider the safety of both the expectant mother and the unborn fetus in the clinical management decisions. This practice guideline provides an evidence-based approach to common diagnostic and treatment challenges of liver disease in pregnant women.

Next